247 related articles for article (PubMed ID: 33876586)
1. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
3. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
Hamilton DK; Vance ML; Boulos PT; Laws ER
Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Endoscopic Transsphenoidal Resection for Prolactinoma: A Retrospective Multicenter Case-series.
Zandbergen IM; Huntoon KM; White TG; Bakker LEH; Verstegen MJT; Ghalib LM; van Furth WR; Pelsma ICM; Dehdashti AR; Biermasz NR; Prevedello DM
Arch Med Res; 2023 Dec; 54(8):102919. PubMed ID: 38040527
[TBL] [Abstract][Full Text] [Related]
5. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.
Babey M; Sahli R; Vajtai I; Andres RH; Seiler RW
Pituitary; 2011 Sep; 14(3):222-30. PubMed ID: 21170594
[TBL] [Abstract][Full Text] [Related]
6. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center.
Andereggen L; Frey J; Andres RH; Luedi MM; El-Koussy M; Widmer HR; Beck J; Mariani L; Seiler RW; Christ E
J Endocrinol Invest; 2021 Dec; 44(12):2621-2633. PubMed ID: 33847973
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
Wei L; Wei X
Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
[TBL] [Abstract][Full Text] [Related]
8. Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients.
Kreutzer J; Buslei R; Wallaschofski H; Hofmann B; Nimsky C; Fahlbusch R; Buchfelder M
Eur J Endocrinol; 2008 Jan; 158(1):11-8. PubMed ID: 18166812
[TBL] [Abstract][Full Text] [Related]
9. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
[TBL] [Abstract][Full Text] [Related]
10. Surgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality.
Kim EH; Kim J; Ku CR; Lee EJ; Kim SH
Yonsei Med J; 2023 Aug; 64(8):489-496. PubMed ID: 37488700
[TBL] [Abstract][Full Text] [Related]
11. Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.
Giese S; Nasi-Kordhishti I; Honegger J
Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):163-171. PubMed ID: 33461233
[TBL] [Abstract][Full Text] [Related]
12. Operative treatment of cystic prolactinomas: a retrospective study.
Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
[TBL] [Abstract][Full Text] [Related]
13. Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis.
Zamanipoor Najafabadi AH; Zandbergen IM; de Vries F; Broersen LHA; van den Akker-van Marle ME; Pereira AM; Peul WC; Dekkers OM; van Furth WR; Biermasz NR
J Clin Endocrinol Metab; 2020 Mar; 105(3):e32-41. PubMed ID: 31665485
[TBL] [Abstract][Full Text] [Related]
14. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
15. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
[TBL] [Abstract][Full Text] [Related]
16. Giant prolactinomas: clinical management and long-term follow up.
Shrivastava RK; Arginteanu MS; King WA; Post KD
J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
[TBL] [Abstract][Full Text] [Related]
17. The Combination of Dopamine Agonist Treatment and Surgery May Be the Best Option in Challenging Prolactinoma Cases: A Single-Centre Experience.
Demir D; Demir AN; Sulu C; Zulfaliyeva G; Cetintas SC; Ozkaya HM; Kadioglu P; Gazioglu N; Tanriover N
World Neurosurg; 2023 Jul; 175():e1166-e1174. PubMed ID: 37120141
[TBL] [Abstract][Full Text] [Related]
18. Surgery as first-line treatment for prolactinoma? Discussion of the literature and results of a consecutive series of surgically treated patients.
Ottenhausen M; Conrad J; Wolters LM; Ringel F
Neurosurg Rev; 2023 May; 46(1):128. PubMed ID: 37249700
[TBL] [Abstract][Full Text] [Related]
19. [Transsphenoidal surgery for prolactinomas: results and prognosis].
Sinkūnas K; Rastenyte D; Deltuva VP; Knispelis R; Tamasauskas A
Medicina (Kaunas); 2007; 43(9):691-7. PubMed ID: 17986841
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long?
Guitelman M
Front Horm Res; 2006; 35():88-101. PubMed ID: 16809925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
